Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company committed to developing novel, optimized therapies for immuno-inflammatory diseases. Their focus is on identifying and advancing drug candidates that have the potential to address significant unmet medical needs. Aclaris leverages its scientific expertise to build a pipeline of innovative treatments, primarily in areas such as rheumatology and other autoimmune conditions. The company is dedicated to rigorous scientific research and clinical development to bring new therapeutic options to patients.
Serves as the central hub for corporate administration, clinical development leadership, research strategy, business development, and financial operations.
Modern office and potentially laboratory facilities designed to support biopharmaceutical research and development. The space is likely configured to foster collaboration among scientific, clinical, and administrative teams.
Aclaris fosters a dynamic, science-driven work environment focused on innovation, collaboration, and a commitment to addressing unmet medical needs. The culture emphasizes scientific excellence, agility, and a patient-centric approach, typical of a clinical-stage biotech company.
The headquarters is pivotal for Aclaris's mission, housing key decision-makers and the core infrastructure for advancing its pipeline of novel therapies. Its location in the Greater Philadelphia area places it within a prominent pharmaceutical and biotechnology hub, facilitating access to talent and industry networks.
Aclaris Therapeutics primarily operates from its US headquarters in Wayne, Pennsylvania. Its global presence is mainly characterized by the execution of clinical trials in various international locations as required for its drug development programs. The company also engages with the global scientific and medical community through research collaborations, presentations at international conferences, and partnerships to advance its immuno-inflammatory disease therapies.
640 Lee Road, Suite 200
Wayne
PA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Aclaris Therapeutics, Inc.' leadership includes:
Aclaris Therapeutics, Inc. has been backed by several prominent investors over the years, including:
Aclaris Therapeutics strengthened its executive team with a key appointment in business and strategy over the past year, reflecting its focus on advancing its clinical pipeline and strategic growth initiatives. No major C-level departures were publicly announced during this period.
Discover the tools Aclaris Therapeutics, Inc. uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Aclaris Therapeutics Inc. commonly uses the 'firstinitiallast' email format for its employees. Other formats might exist but this is understood to be a prevalent one.
[first_initial][last]@aclaristx.com
Format
jdoe@aclaristx.com
Example
85%
Success rate
GlobeNewswire • May 7, 2024
Aclaris announced its financial results for the first quarter ended March 31, 2024, and provided updates on its clinical programs, including progress on ATI-1777 and ATI-2138....more
GlobeNewswire • February 27, 2024
Aclaris reported its financial results for the fourth quarter and full year 2023, highlighting clinical advancements and outlining strategic priorities for its development pipeline....more
GlobeNewswire • January 4, 2024
Aclaris announced that its Phase 2b study of ATI-1777 for atopic dermatitis did not meet its primary endpoint, leading to a strategic decision to discontinue development of ATI-1777 for this indication and to explore strategic alternatives for the asset....more
GlobeNewswire • September 7, 2023
Aclaris announced the appointment of Robert A. Dalesandro as its new Chief Business and Strategy Officer, effective September 5, 2023....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Aclaris Therapeutics, Inc., are just a search away.